Pharma Compliance in Japan/AU/KR

@EightVeer

Hi there, We can help map the regulatory path for your pharmaceutical product across Japan, Australia, and South Korea in a clear, practical format for your regulatory affairs team. We will compare PMDA, TGA, and MFDS expectations for dossier structure, GMP evidence, labeling, language, and post-market duties, while also highlighting likely sequencing issues and country-specific differences in pharmacovigilance and stability data. Our initial assumption is that the product class and current development stage are still being confirmed, so we will build the roadmap around explicit assumptions and gap points. The platform bid covers an initial phase focused on A consolidated regulatory discovery and comparative roadmap for Japan, Australia, and South Korea, covering product classification assumptions, dossier outline, GMP evidence needs, labeling/language considerations, post-; wider implementation would be separately scoped on Freelancer. Best Regards, 8veer

@salonig54

Dear Client, I am a qualified Company Secretary with experience in regulatory compliance, legal research, and preparing structured compliance documentation. I understand that you require a comparative roadmap for PMDA (Japan), TGA (Australia), and MFDS (South Korea). I can conduct detailed research using official regulatory guidance and prepare a well-organized report covering regulatory pathways, documentation requirements, GMP expectations, labeling, timelines, pharmacovigilance, and post-market obligations. While my core background is in corporate compliance rather than pharmaceutical product registration, I focus on delivering accurate, well-researched, and professionally structured documentation with clear references. I am committed to timely delivery, clear communication, and revisions based on your feedback. I would be pleased to discuss your specific requirements. Kind Regards, CS Saloni